Cargando…
The safety of COVID-19 vaccines in patients with myasthenia gravis: A scoping review
BACKGROUND: COVID-19 vaccines are required for individuals with myasthenia gravis (MG), as these patients are more likely to experience severe pneumonia, myasthenia crises, and higher mortality rate. However, direct data on the safety of COVID-19 vaccines in patients with MG are lacking, which resul...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9812949/ https://www.ncbi.nlm.nih.gov/pubmed/36618419 http://dx.doi.org/10.3389/fimmu.2022.1103020 |
_version_ | 1784863825882775552 |
---|---|
author | Peng, Siyang Tian, Yukun Meng, Linghao Fang, Ruiying Chang, Weiqian Yang, Yajing Li, Shaohong Shen, Qiqi Ni, Jinxia Zhu, Wenzeng |
author_facet | Peng, Siyang Tian, Yukun Meng, Linghao Fang, Ruiying Chang, Weiqian Yang, Yajing Li, Shaohong Shen, Qiqi Ni, Jinxia Zhu, Wenzeng |
author_sort | Peng, Siyang |
collection | PubMed |
description | BACKGROUND: COVID-19 vaccines are required for individuals with myasthenia gravis (MG), as these patients are more likely to experience severe pneumonia, myasthenia crises, and higher mortality rate. However, direct data on the safety of COVID-19 vaccines in patients with MG are lacking, which results in hesitation in vaccination. This scoping was conducted to collect and summarize the existing evidence on this issue. METHODS: PubMed, Cochrane Library, and Web of Science were searched for studies using inclusion and exclusion criteria. Article titles, authors, study designs, demographics of patients, vaccination information, adverse events (AEs), significant findings, and conclusions of included studies were recorded and summarized. RESULTS: Twenty-nine studies conducted in 16 different countries in 2021 and 2022 were included. Study designs included case report, case series, cohort study, cross-sectional study, survey-based study, chart review, and systemic review. A total of 1347 patients were included. The vaccines used included BNT162b2, mRNA-1273, ChAdOx1 nCoV-19, inactivated vaccines, and recombinant subunit vaccines. Fifteen case studies included 48 patients reported that 23 experienced new-onset, and five patients experienced flare of symptoms. Eleven other types of studies included 1299 patients reported that nine patients experienced new-onset, and 60 participants experienced flare of symptoms. Common AEs included local pain, fatigue, asthenia, cephalalgia, fever, and myalgia. Most patients responded well to treatment without severe sequelae. Evidence gaps include limited strength of study designs, type and dose of vaccines varied, inconsistent window of risk and exacerbation criteria, limited number of participants, and lack of efficacy evaluation. CONCLUSION: COVID-19 vaccines may cause new-onset or worsening of MG in a small proportion of population. Large-scale, multicenter, prospective, and rigorous studies are required to verify their safety. |
format | Online Article Text |
id | pubmed-9812949 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-98129492023-01-06 The safety of COVID-19 vaccines in patients with myasthenia gravis: A scoping review Peng, Siyang Tian, Yukun Meng, Linghao Fang, Ruiying Chang, Weiqian Yang, Yajing Li, Shaohong Shen, Qiqi Ni, Jinxia Zhu, Wenzeng Front Immunol Immunology BACKGROUND: COVID-19 vaccines are required for individuals with myasthenia gravis (MG), as these patients are more likely to experience severe pneumonia, myasthenia crises, and higher mortality rate. However, direct data on the safety of COVID-19 vaccines in patients with MG are lacking, which results in hesitation in vaccination. This scoping was conducted to collect and summarize the existing evidence on this issue. METHODS: PubMed, Cochrane Library, and Web of Science were searched for studies using inclusion and exclusion criteria. Article titles, authors, study designs, demographics of patients, vaccination information, adverse events (AEs), significant findings, and conclusions of included studies were recorded and summarized. RESULTS: Twenty-nine studies conducted in 16 different countries in 2021 and 2022 were included. Study designs included case report, case series, cohort study, cross-sectional study, survey-based study, chart review, and systemic review. A total of 1347 patients were included. The vaccines used included BNT162b2, mRNA-1273, ChAdOx1 nCoV-19, inactivated vaccines, and recombinant subunit vaccines. Fifteen case studies included 48 patients reported that 23 experienced new-onset, and five patients experienced flare of symptoms. Eleven other types of studies included 1299 patients reported that nine patients experienced new-onset, and 60 participants experienced flare of symptoms. Common AEs included local pain, fatigue, asthenia, cephalalgia, fever, and myalgia. Most patients responded well to treatment without severe sequelae. Evidence gaps include limited strength of study designs, type and dose of vaccines varied, inconsistent window of risk and exacerbation criteria, limited number of participants, and lack of efficacy evaluation. CONCLUSION: COVID-19 vaccines may cause new-onset or worsening of MG in a small proportion of population. Large-scale, multicenter, prospective, and rigorous studies are required to verify their safety. Frontiers Media S.A. 2022-12-22 /pmc/articles/PMC9812949/ /pubmed/36618419 http://dx.doi.org/10.3389/fimmu.2022.1103020 Text en Copyright © 2022 Peng, Tian, Meng, Fang, Chang, Yang, Li, Shen, Ni and Zhu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Peng, Siyang Tian, Yukun Meng, Linghao Fang, Ruiying Chang, Weiqian Yang, Yajing Li, Shaohong Shen, Qiqi Ni, Jinxia Zhu, Wenzeng The safety of COVID-19 vaccines in patients with myasthenia gravis: A scoping review |
title | The safety of COVID-19 vaccines in patients with myasthenia gravis: A scoping review |
title_full | The safety of COVID-19 vaccines in patients with myasthenia gravis: A scoping review |
title_fullStr | The safety of COVID-19 vaccines in patients with myasthenia gravis: A scoping review |
title_full_unstemmed | The safety of COVID-19 vaccines in patients with myasthenia gravis: A scoping review |
title_short | The safety of COVID-19 vaccines in patients with myasthenia gravis: A scoping review |
title_sort | safety of covid-19 vaccines in patients with myasthenia gravis: a scoping review |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9812949/ https://www.ncbi.nlm.nih.gov/pubmed/36618419 http://dx.doi.org/10.3389/fimmu.2022.1103020 |
work_keys_str_mv | AT pengsiyang thesafetyofcovid19vaccinesinpatientswithmyastheniagravisascopingreview AT tianyukun thesafetyofcovid19vaccinesinpatientswithmyastheniagravisascopingreview AT menglinghao thesafetyofcovid19vaccinesinpatientswithmyastheniagravisascopingreview AT fangruiying thesafetyofcovid19vaccinesinpatientswithmyastheniagravisascopingreview AT changweiqian thesafetyofcovid19vaccinesinpatientswithmyastheniagravisascopingreview AT yangyajing thesafetyofcovid19vaccinesinpatientswithmyastheniagravisascopingreview AT lishaohong thesafetyofcovid19vaccinesinpatientswithmyastheniagravisascopingreview AT shenqiqi thesafetyofcovid19vaccinesinpatientswithmyastheniagravisascopingreview AT nijinxia thesafetyofcovid19vaccinesinpatientswithmyastheniagravisascopingreview AT zhuwenzeng thesafetyofcovid19vaccinesinpatientswithmyastheniagravisascopingreview AT pengsiyang safetyofcovid19vaccinesinpatientswithmyastheniagravisascopingreview AT tianyukun safetyofcovid19vaccinesinpatientswithmyastheniagravisascopingreview AT menglinghao safetyofcovid19vaccinesinpatientswithmyastheniagravisascopingreview AT fangruiying safetyofcovid19vaccinesinpatientswithmyastheniagravisascopingreview AT changweiqian safetyofcovid19vaccinesinpatientswithmyastheniagravisascopingreview AT yangyajing safetyofcovid19vaccinesinpatientswithmyastheniagravisascopingreview AT lishaohong safetyofcovid19vaccinesinpatientswithmyastheniagravisascopingreview AT shenqiqi safetyofcovid19vaccinesinpatientswithmyastheniagravisascopingreview AT nijinxia safetyofcovid19vaccinesinpatientswithmyastheniagravisascopingreview AT zhuwenzeng safetyofcovid19vaccinesinpatientswithmyastheniagravisascopingreview |